📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Hemostemix

1.1 - Company Overview

Hemostemix Logo

Hemostemix

Headquarter: Canada
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of autologous cell therapies derived from a patient's own blood, including ACP-01 to regenerate blood flow and tissue for ischemic conditions such as critical limb ischemia, peripheral arterial disease, angina, and ischemic cardiomyopathy, and NCP-01, a neuronal cell precursor therapy aimed at treating central and peripheral nervous system conditions including neuropathic pain, spinal cord injuries, and stroke.

Products and services

  • NCP-01: An autologous neuronal cell precursor therapy derived from a patient’s own blood, aimed at treating central and peripheral nervous system conditions including neuropathic pain, spinal cord injuries, and stroke
  • ACP-01: An autologous stem cell therapy derived from a patient’s own blood that regenerates blood flow and tissue to treat critical limb ischemia, peripheral arterial disease, angina, and ischemic cardiomyopathy.

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Hemostemix

Avenu Medical Logo

Avenu Medical

HQ: United States Website
  • Description: Provider of the Ellipsys Vascular Access System, a minimally invasive solution for creating arteriovenous fistulas in hemodialysis patients, using thermal energy to fuse tissue without leaving foreign materials, pursuing unmet clinical needs with cost-effective, efficient approaches to vascular access.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Avenu Medical company profile →
MedAlliance Logo

MedAlliance

HQ: Switzerland Website
  • Description: Provider of innovative drug-eluting balloons (DEBs) for treating coronary and peripheral arterial disease.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full MedAlliance company profile →
IDEV Logo

IDEV

HQ: United States Website
  • Description: Provider of endovascular and interventional medical devices, marketing SUPERA, a novel self-expanding nitinol stent with a patented interwoven design that enhances flexibility, radial strength, and resistance to kinking and crushing.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full IDEV company profile →
Exithera Pharmaceuticals Logo

Exithera Pharmaceuticals

HQ: United States Website
  • Description: Provider of antithrombotic and stroke prevention drug development, offering novel, potent, selective small-molecule Factor XIa inhibitors, including frunexian to prevent thrombosis without increased bleeding risk, and EP-7041 evaluated in a Phase 2 trial to prevent thrombosis in COVID-19 ICU patients and investigated to inhibit ECMO-related thrombosis while minimizing bleeding risk.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Exithera Pharmaceuticals company profile →
Capstan Medical Logo

Capstan Medical

HQ: United States Website
  • Description: Provider of minimally invasive catheter-based technologies for heart valve disorders, including the Capstan Platform for treating mitral and tricuspid valve disease while the heart is beating, precision heart valve implants placed through a catheter, and surgical robotics integration to enhance procedure accuracy and reliability, offering a less invasive alternative to open heart surgery.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Capstan Medical company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Hemostemix

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Hemostemix

2.2 - Growth funds investing in similar companies to Hemostemix

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Hemostemix

4.2 - Public trading comparable groups for Hemostemix

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Hemostemix

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Hemostemix

What does Hemostemix do?

Hemostemix is a provider of autologous cell therapies derived from a patient's own blood, including ACP-01 to regenerate blood flow and tissue for ischemic conditions such as critical limb ischemia, peripheral arterial disease, angina, and ischemic cardiomyopathy, and NCP-01, a neuronal cell precursor therapy aimed at treating central and peripheral nervous system conditions including neuropathic pain, spinal cord injuries, and stroke.

Who are Hemostemix's competitors?

Hemostemix's competitors and similar companies include Avenu Medical, MedAlliance, IDEV, Exithera Pharmaceuticals, and Capstan Medical.

Where is Hemostemix headquartered?

Hemostemix is headquartered in Canada.

How many employees does Hemostemix have?

Hemostemix has 1,000 employees 🔒.

When was Hemostemix founded?

Hemostemix was founded in 2010 🔒.

What sector and industry vertical is Hemostemix in?

Hemostemix is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Hemostemix

Who are the top strategic acquirers in Hemostemix's sector and industry

Top strategic M&A buyers and acquirers in Hemostemix's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Hemostemix?

Top strategic M&A buyers groups and sectors for Hemostemix include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Hemostemix's sector and industry vertical

Which are the top PE firms investing in Hemostemix's sector and industry vertical?

Top PE firms investing in Hemostemix's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Hemostemix's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Hemostemix's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Hemostemix's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Hemostemix include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Hemostemix's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Hemostemix?

The key public trading comparables and valuation benchmarks for Hemostemix include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Hemostemix for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Hemostemix with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Hemostemix's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Hemostemix with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Hemostemix's' sector and industry vertical?

Access recent funding rounds and capital raises in Hemostemix's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Hemostemix